APOA4

(redirected from apoA-IV)

APOA4

A gene on chromosome 11q23 that encodes apolipoprotein A-IV, which is a major component of high-density lipoprotein (HDL) and chylomicrons. It plays a role in chylomicrons and VLDL secretion and catabolism, and is required for efficient activation of lipoprotein lipase by ApoC-II. It is a potent activator of lecithin-cholesterol acyltransferase (LCAT).
Mentioned in ?
References in periodicals archive ?
It has been found that ApoA-IV has the ability to reduce blood sugar levels and enhance insulin secretion.
Previous studies have found ApoA-IV to be elevated in humans following gastric bypass-coinciding with improvement in symptoms for diabetes.
Carrying out their study on lab mice, Tso's team found that mice deficient in apoA-IV had impaired glucose tolerance and insulin was not secreted to move glucose from the blood stream.
However, when injected with apoA-IV, these same mice showed improved insulin response to glucose, despite a diet high in fat.
Tso's team also tested the response to injected apoA-IV in diabetic mice and found that it reduced glucose levels among that group as well.
Tso claimed that their research shows apoA-IV to behave similar to an incretin-a gastrointestinal hormone causing an increased release of insulin after eating to combat the onset of elevated blood glucose.
The research published in the current online early edition of the Proceedings of the National Academy of Sciences (PNAS), suggests apoA-IV is a promising new target for developing treatments for Type 2 diabetes.
Studies have also shown that apoA-IV is significantly increased in humans following gastric bypass, and this was coincident with the amelioration of diabetes.
Our studies have identified a novel function of apoA-IV as a potent regulator of insulin secretion and glucose homeostasis," stated Dr.
Apofore was established to advance this promising research, beginning with a recombinant form of apoA-IV, into clinical trials to determine its potential role in the diabetes treatment paradigm.
Tso and his team studied mice that were deficient in apoA-IV (known as apoA-IV(-/-) knockout mice) and found that these knockout mice had reduced insulin secretion and impaired glucose tolerance.
The percentage of ApoA-IV amounts to only one-tenth of that of the ApoA-II (13) and can be neglected.